

## RULE 1.3/1.4 - PROFORMA APPLICATION ANNOUNCEMENT

### Guidance

In accordance with Rule 1.3 of the Apex Rulebook/ Rule 1.4 of the Access Rulebook, an AQSE Corporate Adviser must submit the information requested in the form set out below no less than 10 business days prior to the intended admission date.

AQSE will release the pre-admission announcement by RIS under the heading "AQSE" on the date of submission of the form.

In the event information is not known at the time of submission, "TBC" may be stated in the relevant section. As soon as such information is known, the AQSE Corporate Adviser must submit an updated form with the updates narrated in bold.

<p>Please submit the form by email in an MS Word document to <a href="mailto:aqseregulation@aqis.eu">aqseregulation@aqis.eu</a>.</p> <p><b>ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQSE GROWTH MARKET</b></p>
<b>APPLICANT NAME:</b>
PHARMA C INVESTMENTS PLC
<b>APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER:</b>
Registered Office: 85 First Floor Great Portland Street London, United Kingdom W1W 7LT
Business Address: 19 Compton Avenue London N1 2XD
Telephone number: 07897 834092 (Chana Greenberg, CEO)
<b>DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE):</b>
Nicola ("Chana") Anne Greenberg ( <i>Chief Executive Officer</i> ) Sharon Natalie Segal ( <i>Non-Executive Director and Chairperson</i> ) Gavin Hilary Sathianathan ( <i>Director of Investment Strategy</i> )
<b>APPLICANT SECTOR:</b>
Financial Services
<b>DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES:</b>
The Company was incorporated on 28 August 2018 as an investment vehicle (being a SPAC under the AQSE Growth Market Access Rulebook) to identify investment opportunities and make acquisitions in companies; it is specifically seeking to take advantage of the dynamic regulatory environment surrounding legal Medicinal Cannabis.
The Company will focus on identifying investment opportunities in companies that provide ancillary products and services which serve the Medicinal Cannabis sector, not just in Europe, but in markets globally (with a particular focus on the United Kingdom, Europe and Israel) that are internationally recognised as having well-

developed and reputable laws and regulations for the research and production of Medicinal Cannabis and that comply with the United Nations' Convention on Narcotic Drugs. The Company expects to provide investee companies with strategic insights, assist with helping them realise their growth strategy and provide operational support as they develop.

**NAME OF AQSE CORPORATE ADVISER:**

BEAUMONT CORNISH LIMITED

**NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED:**

269,857,144 Ordinary Shares of 0.25p per Share par value

**SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury):**

72.95%

**SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT'S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION:**

Shareholder	Shareholding	% of pre-admission issued share capital	% of Issued Share Capital on Admission
Noel Lyons	26,700,000	21.0%	9.89%
Paul Ryan	23,000,001	18.1%	8.52%
Gavin Sathianathan	23,300,000	18.3%	8.63%
Nicholas True	12,000,000	9.4%	4.45%
Eugenio Marrapodi	12,000,000	9.4%	4.45%
Nik West	12,000,000	9.4%	4.45%
Chris Simpson	10,000,000	7.9%	3.71%

**TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC:**

N/A

**THE EXPECTED ADMISSION DATE:**

26 May 2021

**WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION:**

[www.pharmacinvestments.com](http://www.pharmacinvestments.com)

*In respect of a fast-track applicant, the following information should also be included:*

**NAME OF MARKET ON WHICH THE APPLICANT'S SECURITIES ARE CURRENTLY TRADED:**

N/A

**ARRANGEMENTS FOR THE SETTLEMENT OF TRANSACTIONS IN THE APPLICANT'S SECURITIES:**

N/A

**DETAILS OF ANY LOCK-IN ARRANGEMENTS:**

N/A

**DETAILS OF THE LEGAL OR REGULATORY REQUIREMENTS IN THE APPLICANT'S HOME COUNTRY REGARDING THE CONDUCT OF TAKEOVERS AND THE ACQUISITION OF SIGNIFICANT VOTING RIGHTS TO WHICH THE APPLICANT IS SUBJECT:**

N/A

*In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows:*

**UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON:**

N/A